Document:

www.EXFILE.com  888.775.4789   MATRITECH, INC.  FORM 8K == EXHIBIT 4.4

    EXHIBIT
      4.4

    
 

    SECOND
      AMENDED AND RESTATED

    CONTINGENT
      LICENSE AGREEMENT

    

    This
      SECOND AMENDED AND RESTATED CONTINGENT LICENSE AGREEMENT (this
“Agreement”) is made as of the 30th day of August, 2007 (the
“Effective Date”), by and among MATRITECH, INC. a corporation organized
      under the laws of the State of Delaware (the “Licensor”), and SDS CAPITAL
      GROUP SPC, LTD. (the “Licensee”), as collateral agent for the holders
      (the “Holders”) of the Series A Notes, Series B Notes and Series C Notes
      (as defined below) (in such capacity, the “Collateral
      Agent”).

    

    WHEREAS,
      the Licensor and certain Holders entered a certain Securities Purchase
      Agreement, dated as of January 13, 2006 (as the same may be amended, restated,
      modified, supplemented and/or replaced from time to time, the “Series A
      Purchase Agreement”), pursuant to which the Licensor issued its 15% Secured
      Convertible Promissory Notes to such  Holders (the “Series A Note
      Holders”) in the original aggregate principal amount of $6,997,960 (as the
      same may be amended, restated, modified, supplemented and/or replaced from
      time
      to time, the “Series A Notes”);

    

    WHEREAS,
      in order to induce the Series A Note Holders to purchase the Series A Notes,
      the
      Licensor executed and delivered to the Collateral Agent a Security Agreement,
      dated as of January 13, 2006 (the “Initial Security Agreement”), pursuant
      to which the Licensor granted to the Collateral Agent, for the benefit of itself
      and the Series A Note Holders, a perfected security interest in certain property
      of the Licensor to secure the prompt payment, performance and discharge in
      full
      of all of Borrower’s obligations under the Series A Notes;

    

    WHEREAS,
      in connection with the Series A Purchase Agreement, concurrently therewith,
      the
      Licensor and the Collateral Agent entered into a Contingent License Agreement,
      dated as of January 13, 2006 (the “Initial Contingent License
      Agreement”), pursuant to which the Licensor granted to the Collateral Agent,
      for the benefit of itself and the Series A Note Holders, a contingent license
      under the Matritech Patent Rights, the Matritech Trademark Rights and the MIT
      Patent Rights (each as defined therein) on the terms and conditions set forth
      therein;

    

    WHEREAS,
      the Licensor and certain Holders entered into a Securities Purchase Agreement,
      dated as of January 22, 2007 (as the same may be amended, restated, modified,
      supplemented and/or replaced from time to time, the “Series B Purchase
      Agreement”), pursuant to which the Licensor issued its Series B 15% Secured
      Convertible Promissory Notes to such Holders (the “Series B Note
      Holders”) in the original aggregate principal amount of up to $4,500,000 (as
      the same may be amended, restated, modified, supplemented and/or replaced from
      time to time, the “Series B Notes”);

     

    WHEREAS,
      in connection with the Series B Purchase Agreement, concurrently therewith,
      the
      holders of a majority of outstanding principal balance of the Series A Notes
      consented to the issuance of the Series B Notes and directed the Collateral
      Agent to amend and restate the Initial Security Agreement and Initial Contingent
      License Agreement to enable the Series B Note Holders to have a pari
      passu position with the Series A Note Holders as to the

     

     

     

     

     

    
      
         

      

      
        1

        
          

        

      

      
         

      

    

     security
      interest and license granted under such agreements, and the Initial Security
      Agreement and Initial Contingent License Agreement were so amended and restated
      (as heretofore amended, the “Existing Security Agreement” and
“Existing Contingent License,” respectively).

    

    WHEREAS,
      concurrently herewith, Borrower and certain Holders are entering into a
      Securities Purchase Agreement, dated as of the date hereof (as the same may
      be
      amended, restated, modified, supplemented and/or replaced from time to time,
      the
“Series C Purchase Agreement”, and, together with the Series A Purchase
      Agreement and the Series B Purchase Agreement, the “Purchase Agreements”)
      pursuant to which Borrower is issuing Series C 15% Secured Promissory Notes
      to
      such Holders (the “Series C Note Holders” and together with the Series A
      Note Holders and the Series B Note Holders, the “Holders”) in the
      original aggregate principal amount of $3,330,000 (as the same may be amended,
      restated, modified, supplemented and/or replaced from time to time, the
“Series C Notes” and together with the Series A Notes and Series B Notes,
      the “Notes”).

    

    WHEREAS,
      concurrently herewith, the holders of a majority of outstanding principal
      balance of the Series A Notes, and the holders of a majority of outstanding
      principal balance of the Series B Notes, have consented to the issuance of
      the
      Series B Notes and directed the Collateral Agent to amend and restate the
      Existing Security Agreement and Existing Contingent License Agreement to enable
      the Series C Note Holders to have a pari passu position with the Series
      A Note Holders and the Series B Note Holders as to the security interest and
      license granted under such agreements;

    

    WHEREAS,
      in connection with the Series C Purchase Agreement, concurrently therewith,
      the
      Licensor and the Collateral Agent are amending and restating the Existing
      Security Agreement (as same may be amended, restated, modified, supplemented
      and/or replaced from time to time, the “Security Agreement”) in order to
      grant to the Collateral Agent, for the benefit of itself and of the Holders,
      a
      perfected security interest in certain property of Licensor to secure the prompt
      payment, performance and discharge in full of all of Licensor’s obligations
      under the Notes, all on the terms and conditions set forth therein;

    

    WHEREAS,
      Licensor is the owner of the Matritech Patent Rights and Matritech Trademark
      Rights (each as defined below) and has the right to sublicense the MIT Patent
      Rights (as defined below); and

    

    WHEREAS,
      in order to induce the Series C Note Holders to extend credit to the Borrower
      under and pursuant to the Series C Notes, the Licensor agrees to amend and
      restate the Existing Contingent License Agreement in order to grant to Licensee,
      for the benefit of itself and the Holders, a contingent license under the
      Matritech Patent Rights, the Matritech Trademark Rights and the MIT Patent
      Rights on the terms and conditions set forth in this Agreement;

    

    NOW,
      THEREFORE, in consideration of the foregoing and the mutual covenants contained
      herein, and for other good and valuable consideration, the receipt and
      sufficiency of which are hereby acknowledged, the parties hereto agree to amend
      and restate the Existing Contingent License Agreement so that, as amended and
      restated, it reads in its entirety as provided herein:

     

     

     

     

     

    
 

    
      
         

      

      
        2

        
          

        

      

      
         

      

    

    1.  
Definitions.

     

    (a)  “Abbott
      License Agreement”  shall mean the license agreement entered into
      by and between Abbott Laboratories and Matritech, Inc., effective April 1,
      2004.

     

    (b)  “Event
      of Default” shall mean any Event of Default described in (1) Sections A(i),
      (ii) or (iii) of Article VI of the Series C Notes; (2) Sections A(i), (vi)
      or
      (vii) of Article VI of the Series B Notes; or (3) Sections A(i), (vi) or (vii)
      of Article VI of the Series A Notes.

     

    (c)  “Expiration
      Date” shall mean the earlier to occur of the date on which (i) on a
      country-by-country basis, the expiration of the last to expire of any Valid
      Claim included in the Matritech Patent Rights and the MIT Patent Rights in
      such
      country, (ii) all principal, premium, if any, interest on the Notes, and any
      other amounts payable pursuant to the terms of the Notes have been paid in
      full,
      or (iii) receipt of payments by the Licensee on net profits on the sales of
      Licensed Products hereunder that equal the unpaid balance of all principal,
      premium, if any, interest on the Notes, and any other amounts payable pursuant
      to the terms of the Notes.

     

    (d)  “Field”
      shall mean the field of bladder cancer detection in humans.

     

    (e)  “License
      Agreements”  shall mean the MIT License Agreement and the Abbott
      License Agreement.

     

    (f)  “Licensed
      Products” shall mean any human bladder cancer detection product, including
      without limitation the NMP22® BladderChek® Test and the NMP22® Test Kit,
      developed, marketed, and/or sold by Licensee.

     

    (g)  “License
      Term” shall mean the period commencing on the effective date of an Event of
      Default and continuing until the Expiration Date.

     

    (h)  “Matritech
      Patent Rights” shall mean the patent rights listed on Schedule A, and
      any continuation, continuation-in-part, divisional, reexamination, or reissue
      thereof, and any foreign counterpart patents and patent applications to any
      of
      the foregoing.

     

    (i)  “Matritech
      Trademark Rights” shall means the trademark rights listed on Schedule
      B and the goodwill of the business symbolized thereby, and related
      registrations and applications for registration to any of the
      foregoing.

     

    (j)  “MIT
      License Agreement” shall mean the license agreement entered into by and
      between Massachusetts Institute of Technology (“MIT”) and Matritech,
      Inc., effective December 14, 1987 attached hereto as Schedule
      F.

     

     

     

     

    
      
         

      

      
        3

        
          

        

      

      
         

      

    

    (k)  “MIT
      Patent Rights” shall mean the patent rights listed on Schedule C, and
      any continuation, continuation-in-part, divisional, reexamination, or reissue
      thereof, and any foreign counterpart patents and patent applications to any
      of
      the foregoing.

     

    (l)  “Permitted
      Amendment” shall mean, with respect to an agreement to which Licensor is a
      party, any amendment, alteration, waiver or other change of any of the terms
      or
      conditions of such agreement in a manner that would not materially adversely
      affect Licensee’s rights or obligations provided under this Agreement with
      respect to such agreement.

     

    (m)  “Secured
      Obligations” shall have the meaning set forth in the Security
      Agreement.

     

    (n)  “Territory”
      shall mean the entire world.

     

    (o)  “Unotech
      Contract” shall mean the Contract and Manufacturing Arrangement entered into
      by and between Unotech Diagnostics, Inc. (“Unotech”) and Matritech, Inc.,
      on March 22, 2001.

     

    (p)  “Valid
      Claim” shall mean a claim of any issued and unexpired patent within the
      Matritech Patent Rights and/or the MIT Patent Rights which has not lapsed,
      become abandoned or been held revoked, invalid, or unenforceable by a decision
      of a court or administrative or government authority or agency of competent
      jurisdiction from which no appeal can be or has been taken within the time
      allowed for such appeal, and which has not been admitted to be invalid or
      unenforceable through reissue, disclaimer or otherwise.

     

    2.  
License
      Grants and Restrictions.

     

    (a)  Matritech
      Patent License Grant.  Subject to (i) the terms and conditions set
      forth in this Agreement, (ii) any license rights granted to Unotech under the
      Unotech Contract, and (iii) any license rights, similar to those granted to
      Unotech under the Unotech Contract, granted to any third party manufacturer,
      Licensor hereby grants to Licensee, and Licensee hereby accepts, an exclusive,
      royalty-free, fully paid-up, right and license under the Matritech Patent Rights
      to make, have made, use, sell, have sold, offer for sale, have offered for
      sale,
      import and have imported Licensed Products in each case within the Field and
      within the Territory during the License Term.  Licensee may
      sublicense, directly or indirectly (through multiple tiers), the rights granted
      to Licensee under this Section 2(a)
      to any entity or person.  The license granted under this Section 2(a)
      shall terminate effective immediately as of the Expiration Date.

     

    (b)  MIT
      Patent Sublicense Grant.  Subject to the terms and conditions set
      forth in this Agreement and the sections of the MIT License Agreement attached
      hereto as Schedule D, Licensor hereby grants to Licensee, and Licensee
      hereby accepts, an exclusive, royalty bearing, right and license under the
      MIT
      Patent Rights to make, have made, use, sell, have sold, offer for sale, have
      offered for sale, import and have imported Licensed Products in each case within
      the Field and within the Territory during the License Term.  Licensee
      may sublicense, directly or indirectly (through multiple tiers), the rights
      granted to Licensee under 

     

     

    
      
         

      

      
        4

        
          

        

      

      
         

      

    

    this
      Section 2(b)
      to any entity or person.  The license granted under this Section 2(b)
      shall terminate effective immediately as of the Expiration Date.

     

    (i)  Licensee
      agrees to be bound by the obligations to MIT set forth in the sections of the
      MIT License Agreement attached hereto as Schedule D as if Licensee were a
      party to the MIT License Agreement.

     

    (c)  Matritech
      Trademark License Grant.

     

    (i)  Subject
      to the terms and conditions set forth in this Agreement, Licensor hereby grants
      to Licensee, and Licensee hereby accepts, an exclusive, royalty-free, fully
      paid-up, right and license under the Matritech Trademark Rights to use and
      display the Matritech Trademark Rights in any and all advertising and other
      promotional materials (whether in traditional print or electronic format)
      relating to the marketing, advertising, promotion, and/or selling of Licensed
      Products within the Field and within the Territory during the License
      Term.  Licensee may sublicense, directly or indirectly (through
      multiple tiers), the rights granted to Licensee under this Section 2(c)
      to any entity or person. The license granted under this Section 2(c)
      shall terminate effective immediately as of the Expiration Date.

     

    (ii)  The
      Licensor and Licensee hereby acknowledge that the Matritech Trademark Rights
      have established goodwill, and acknowledge the importance of Licensor’s control
      over the quality of Licensee’s use thereof so as to preserve the continued
      validity of the Matritech Trademark Rights and to protect the goodwill
      associated therewith.  Licensee agrees that the quality of the
      products and services provided by Licensee under the Matritech Trademark Rights
      shall equal or exceed the standard of quality heretofore established and
      maintained by Licensor with respect to the same or similar products and
      services.  All goodwill resulting from Licensee’s use of the Matritech
      Trademark Rights shall inure to the benefit of Licensor.  If Licensor
      determines that Licensee is using or displaying any Matritech Trademark Rights
      in a manner that is or may be detrimental to Licensor’s interest, Licensor may
      issue reasonable instructions to Licensee concerning the manner, if any, in
      which Licensee may continue to use such Matritech Trademark
      Rights.  Licensee shall promptly comply with such instructions or
      cease the use or display of such Matritech Trademark Rights.

     

    (d)  Sublicenses.  Licensee’s
      right to sublicense under Sections 2(a)
      through 2(c)
      hereunder shall be exclusive to it and may only be made during the License
      Term.  Prior to any sublicense becoming effective, Licensee shall have
      furnished to Licensor a complete copy, including all exhibits and schedules
      thereto, of any sublicense granted by Licensee at least five (5) business days
      prior to the effective date of any such sublicense.  Except as
      Licensor expressly agrees otherwise in writing, any sublicense granted by
      Licensee under this Section 2(d)
      hereof shall be subject and subordinate to the terms of this Agreement, shall
      terminate not later than the Expiration Date and shall provide that all rights
      to the Matritech Patent Rights, MIT Patent Rights and Matritech Trademark Rights
      sublicensed by Licensee to its sublicensee hereunder shall revert exclusively
      to
      Licensor upon the Expiration Date automatically and without further action
      by
      either Licensor or Licensee.

     

     

     

     

     

    
      
         

      

      
        5

        
          

        

      

      
         

      

    

    (e)  Limitation.  The
      licenses granted to Licensee under this Agreement do not confer any right to
      practice the inventions covered by the claims of the Matritech Patent Rights
      and/or the MIT Patent Rights outside of the Field.  Nothing in this
      Agreement shall prevent Licensor, directly or indirectly, from making, having
      made, selling, having sold, offering to sell, having offered for sale,
      importing, having imported, renting, and/or leasing any apparatus, systems
      or
      products outside of the Field which practice or embody, or are configured for
      use in practicing, the inventions covered by the claims of the Matritech Patent
      Rights and/or the MIT Patent Rights, or practicing any method covered by the
      claims of the Matritech Patent Rights and/or the MIT Patent Rights outside
      of
      the Field.  Licensor reserves all rights not expressly granted
      herein.

     

    3.  
Licensed
      Product Marking.  To the extent required by applicable law,
      Licensee agrees to mark each Licensed Product and any and all associated
      materials with the proper patent numbers and patent and trademark notices,
      including without limitation, those patent numbers and notices that are listed
      on the NMP22® BladderChek® Test and the NMP22® Test Kit as of the Effective
      Date.

     

    4.  
Confidentiality
      Obligations.

     

    (a)  “Confidential
      Information” means, subject to the exceptions set forth in Section 4(c),
any and all information included in or representing the Matritech
      Patent
      Rights and/or the MIT Patent Rights and the existence of this Agreement, the
      terms and conditions of this Agreement, and Schedule F to this
      Agreement.

     

    (b)  The
      Licensee shall not disclose any Confidential Information to any third party
      nor
      use any Confidential Information for any purpose except as may be expressly
      authorized by the Licensor in writing.  Notwithstanding the foregoing,
      the Licensee may disclose Confidential Information to the extent required by
      law
      or legal process, provided the Licensor is given reasonable prior written notice
      and a reasonable opportunity to intervene to protect its
      interests.  Licensee hereby acknowledges that the MIT License
      Agreement has been filed with the U.S. Securities and Exchange Commission
      subject to a confidential treatment order with respect to certain portions
      thereof. The Licensee shall not disclose any Confidential Information pursuant
      to law or legal process without first notifying the Licensor and using
      reasonable efforts to minimize such disclosure and, in the case of the MIT
      License Agreement, to prevent the disclosure of the information subject to
      the
      aforesaid confidential treatment order, while such order is in effect. The
      obligations of this Section 4shall
      survive the expiration or termination of this License
      Agreement.

     

    (c)  Information
      will not be deemed Confidential Information hereunder if such information:
      (a)
      is known to the receiving party prior to receipt from the disclosing party
      directly or indirectly from a source other than one having an obligation of
      confidentiality to the disclosing party; (b) becomes known (independently of
      disclosure by the disclosing party) to the receiving party directly or
      indirectly from a source other than one having an obligation of confidentiality
      to the disclosing party; (c) becomes publicly known or otherwise ceases to
      be
      secret or confidential, except through a breach of this Agreement by the
      receiving party; or (d) is independently developed by the receiving
      party.

     

     

     

     

     

     

    
      
         

      

      
        6

        
          

        

      

      
         

      

    

    (d)  Notwithstanding
      anything to the contrary in this Section 4, upon execution of this Agreement,
      the
      parties agree to execute the Notice of License Grant attached hereto as
Schedule E, a copy of which may be recorded with the U.S. Patent and
      Trademark Office together with SchedulesA, B, and C
      attached hereto.

     

    5.  
Records
      and Audit Rights.

     

    (a)  Licensee
      shall maintain (and cause it sublicensees to maintain) complete and accurate
      records of any information which may be reasonably required by Licensor to
      determine whether Licensee is complying with the terms of this
      Agreement.

     

    (b)  For
      the
      sole purpose of determining whether Licensee is in compliance with the terms
      of
      this Agreement, Licensor shall have the right, at Licensor’s expense, to have an
      independent auditor conduct an inspection and audit of all the relevant
      accounting and sales books, records, agreements, and documents of Licensee,
      during regular business hours at Licensee’s offices and in such a manner as not
      to interfere unreasonably with Licensee’s normal business
      activities.  In no event shall such audits be conducted hereunder more
      frequently than every twelve (12) months.  Prior to commencing any
      such inspection and audit, any such independent auditor shall have entered
      into
      an agreement with Licensor which prohibits the disclosure of any information
      relating to Licensee to any party, including Licensor, except that such auditor
      may issue a report to Licensor, the sole purpose of which shall be to report
      to
      Licensor whether Licensee is in compliance with the terms of this Agreement,
      including a summary of and sufficient detail regarding the scope, quality,
      and
      methodology of such compliance or lack thereof.

     

    6.  
Term
      and Termination.

     

    (a)  The
      term
      of this Agreement (“Term”) shall commence on the Effective Date and
      continue until the Expiration Date.

     

    (b)  Upon
      termination or expiration of this Agreement and except as otherwise expressly
      provided herein, the licenses granted hereunder shall terminate, and any
      sublicenses granted by Licensee hereunder shall terminate simultaneously unless
      otherwise agreed to in writing by Licensor.

     

    7.  
Prosecution,
      Maintenance and Enforcement.

     

    (a)  Prosecution
      and Maintenance.  Licensor retains the sole right to prepare,
      file, prosecute, and maintain the patent applications and patents included
      in
      the Matritech Patent Rights and the trademark registrations and applications
      for
      registration included in the Matritech Trademark Rights.  No part of
      this Agreement shall be construed to require Licensor to file any patent or
      trademark application, secure any patent or trademark registration, provide
      copies of patent and/or trademark applications or patents and/or trademark
      registrations to Licensee or disclose any inventions described or claimed in
      such patents or patent applications.  Subject to Section 7(a)(i),
      Licensor agrees to maintain the Matritech Patent Rights and/or Matritech
      Trademark Rights and Licensor shall not abandon, transfer or license any of
      the
      Matritech Patent

     

     

     

     

     

    
      
         

      

      
        7

        
          

        

      

      
         

      

    

    Rights
      and/or Matritech Trademark Rights, in each case that cover the Licensed
      Products, without the prior written approval of the Licensee.

     

    (i)  Option
      of Licensee to Prosecute/Maintain.  Licensor shall give reasonable
      notice to Licensee of any desire to cease prosecution and/or maintenance of
      any
      of the Matritech Patent Rights and/or Matritech Trademark Rights, in each case
      that cover the Licensed Products, on a country by country basis in the
      Territory.  In the event that Licensee wishes Licensor to continue
      prosecution of any such Matritech Patent Rights and/or Matritech Trademark
      Rights, Licensee shall provide timely written instructions to Licensor and
      Licensor agrees to prosecute such Matritech Patent Rights and/or Matritech
      Trademark Rights at Licensor’s expense; provided, that
      Licensor shall not be obligated to prosecute any patent application and/or
      trademark application included in the Matritech Patent Rights and/or Matritech
      Trademark Rights in the event the Licensor determines, in its reasonable
      business judgment, that the prosecution of such application is no longer
      necessary or desirable in the conduct of its business as currently conducted
      or
      as currently proposed to be conducted.  In the event that Licensee
      wishes Licensor to continue maintenance of any such Matritech Patent Rights
      and/or Matritech Trademark Rights, Licensee shall provide timely written
      instructions to Licensor and Licensor agrees to maintain such Matritech Patent
      Rights and/or Matritech Trademark Rights at Licensor’s expense.

     

    (b)  Notice.  In
      the event that Licensee becomes aware of any evidence that (i) any invention
      which is the subject of any patent applications and/or patents included in
      the
      Matritech Patent Rights infringes or is alleged to infringe any third party’s
      patent rights in any field of use, (ii) any patent applications and/or patents
      included in the Matritech Patent Rights is infringed or is alleged to be
      infringed by any third party in any field of use, (iii) any trademark included
      in the Matritech Trademark Rights infringes or is alleged to infringe any third
      party’s trademark rights in any field of use, or (iv) any trademark included in
      the Matritech Trademark Rights is infringed or is alleged to be infringed by
      any
      third party in any field of use, Licensee shall promptly notify Licensor in
      writing of the name and address of such third party, the alleged acts of
      infringement, and any available evidence of infringement.

     

    (c)  Defense
      of Infringement Actions.  Licensor shall defend any claim for
      patent or trademark infringement by a third party on account of the manufacture,
      sale, practice or use of any Licensed Products at its own expense, in its own
      name and entirely under its own direction and control, or settle any such
      action, proceeding or dispute by license.  Notwithstanding the
      foregoing, no settlement of any such action or proceeding which restricts the
      scope, or adversely affects the enforceability, of the Matritech Patent Rights
      and/or Matritech Trademark Rights, in each case that cover the Licensed
      Products, may be entered into by Licensor without the prior written consent
      of
      Licensee, which consent shall not be unreasonably withheld, delayed or
      conditioned.

     

    (d)  Enforcement
      of Patent Rights.  Licensor shall have the sole right, at its sole
      discretion, to bring any legal action for infringement of the Matritech Patent
      Rights and/or the Matritech Trademark Rights or to defend any counterclaim
      of
      invalidity or action of a third party for declaratory judgment of
      non-infringement or interference (“Enforcement Actions”), and

     

     

     

    
      
         

      

      
        8

        
          

        

      

      
         

      

    

    Licensor
      may bring or defend and may settle any such Enforcement Actions solely at its
      own expense and through its counsel.  Any recovery or proceeds of
      settlement or judgment in any Enforcement Actions brought or defended by
      Licensor under this Section 7(d)
      shall be shared in order, as follows: (A) Licensor shall recoup all of its
      reasonable out-of-pocket costs and expenses incurred in connection with such
      Enforcement Action; (B) any balance shall be applied toward the unpaid balance
      of all principal, premium, if any, interest on the Notes, and any other amounts
      payable pursuant to the terms of the Notes; and (C) any and all remaining
      balance shall be received by Licensor.  If Licensor reasonably
      requests, Licensee agrees to become a party to and to participate in any such
      Enforcement Actions, and, without limiting the generality of the foregoing,
      Licensor may implead Licensee as a necessary party to any such legal action
      and
      Licensee agrees to consent to such joinder; provided, however that Licensee’s
      participation shall be at Licensor’s expense.

     

    (i)  Option
      of Licensee to Enforce.  Licensor shall give reasonable notice to
      Licensee of any desire not to pursue any Enforcement Action contemplated by
      Section 7(d).  In
      the event that Licensee wishes Licensor to pursue such Enforcement Action,
      Licensee shall provide timely written instructions to Licensor and Licensor
      agrees to pursue such Enforcement Action in its own name and Licensor and
      Licensee will share the costs and expenses of such Enforcement Action
      equally.  In the event that Licensor recovers any damages or other
      sums in any such action, suit or proceeding or in settlement thereof, such
      damages or other sums recovered shall be shared in order, as follows: (A)
      Licensee shall recoup all of its reasonable out-of-pocket costs and expenses
      incurred in connection with such Enforcement Action; (B) any balance shall
      be
      applied toward the unpaid balance of all principal, premium, if any, interest
      on
      the Notes, and any other amounts payable pursuant to the terms of the Notes;
      and
      (C) any and all remaining balance shall be received by Licensor.

     

    8.
        
Representations
      of Licensor.

     

    (a)  Licensor
      shall not amend, restate, alter, waive or otherwise change any of the terms
      and
      conditions of any License Agreement without the prior written approval of
      Licensee, other than pursuant to a Permitted Amendment.

     

    (b)  Licensor
      represents that, the Matritech Patent Rights, Matritech Trademark Rights, MIT
      Patent Rights, and the intellectual property that is the subject of the Abbott
      License Agreement, are the only intellectual property rights Licensor owns
      or
      has the right to use under any written license agreement that relate to the
      Licensed Products.

     

    9. 
        
Laws
      and Regulations.  Licensee agrees to cause any sublicensee to
      agree, and in the event that Licensee directly tests, manufactures, markets,
      packages, distributes or sells Licensed Products, then Licensee agrees on behalf
      of itself, for the benefit of Licensor to conduct all of its operations dealing
      with Licensed Products in accordance with all applicable laws, regulations
      and
      other requirements, which may be in effect from time to time, of all national
      governmental authorities, and of all states, municipalities and other political
      subdivisions and agencies thereof, including, without limitation the U.S. Food,
      Drug and Cosmetics Act, and the regulations and other requirements of the U.S.
      Food and Drug Administration and to exercise a 

     

     

    
      
         

      

      
        9

        
          

        

      

      
         

      

    

    reasonable
      standard of care in the testing, manufacture, marketing, packaging, distribution
      and sale of any Licensed Product.

     

    10.  
Disclaimer.  EXCEPT
      AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY NOR ITS
      DIRECTORS, OFFICERS, EMPLOYEES, OR AFFILIATES, MAKE ANY REPRESENTATIONS OR
      WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED
      TO
      THE WARRANTY OF TITLE OR THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS
      FOR
      A PARTICULAR PURPOSE, OR NONINFRINGEMENT OR THE VALIDITY OF PATENT CLAIMS,
      ISSUED OR PENDING, OR THE ABSENCE OF LATENT OR OTHER DEFECTS, WHETHER OR NOT
      DISCOVERABLE.  NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A
      REPRESENTATION MADE OR WARRANTY GIVEN BY SUCH PARTY THAT THE EXERCISE BY THE
      OTHER PARTY OF THE LICENSE RIGHTS GRANTED HEREUNDER SHALL NOT INFRINGE ANY
      PATENT OF ANY THIRD PARTY.

     

    11.    
        Limitation
      of Liability.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW,
      IN NO EVENT SHALL EITHER PARTY, ITS DIRECTORS, OFFICERS, EMPLOYEES OR AFFILIATES
      BE LIABLE HEREUNDER FOR SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES OF ANY
      KIND, INCLUDING ECONOMIC DAMAGE OR INJURY TO PROPERTY AND LOST PROFITS,
      REGARDLESS OF WHETHER THE OTHER PARTY SHALL BE ADVISED, SHALL HAVE OTHER REASON
      TO KNOW, OR IN FACT SHALL KNOW, OF THE POSSIBILITY OF THE
      FOREGOING.

     

    12.    
        Section
      365(n) of the Bankruptcy Code.  All rights and licenses granted by
      Licensor under or pursuant to this Agreement are, for all purposes of Section
      365(n) of Title 11 of the United States Code (“Title 11”), licenses of
      rights to “intellectual property” as defined in Title
      11.  Licensor agrees that, in the event of the commencement of
      bankruptcy proceedings by or against Licensor under Title 11, Licensee, as
      licensee of such rights under this Agreement, shall retain and may fully
      exercise all of its rights under this Agreement (including the licenses granted
      hereunder) and all of its rights and elections under Title
      11.  Without limiting the generality of the foregoing, if this
      Agreement is terminated under any applicable insolvency law, or Licensor or
      an
      administrator refuses to further perform this Agreement (or any of Licensor’s
      obligations hereunder) under any applicable insolvency law, then Licensee may
      elect to retain all of its license rights under this Agreement (including
      without limitation the rights described in Section 2 herein) for the remainder of the
      term of
      this Agreement.

     

    13.    
        Relationship
      of Parties.  Nothing herein shall be construed to create any
      partnership, joint venture, agency or similar relationship, or to subject the
      parties to any implied duties or obligations respecting the conduct of their
      affairs which are not expressly stated herein.  Neither party shall
      have any right or authority to assume or create any obligation or
      responsibility, either express or implied, on behalf of or in the name of the
      other party, or to bind the other party in any matter or thing
      whatsoever.

     

     

     

     

     

     

    
      
         

      

      
        10

        
          

        

      

      
         

      

    

    14.    
        Entire
      Agreement.  Each party acknowledges that it has read this
      Agreement, fully understands it, and agrees to be bound by its terms and further
      agrees that it is the complete and exclusive statement of the agreement between
      the parties, which supersedes and merges all prior proposals, understandings
      and
      all other agreements, oral and written between the parties relating to the
      subject matter of this Agreement.  This Agreement cannot be modified
      or altered except by a written instrument duly executed by the Licensor and
      the
      Collateral Agent and consented to by (i) the holders of at least a majority
      of
      the aggregate outstanding principal balance of the Series A Notes and (ii)
      the
      holders of at least a majority of the aggregate outstanding principal balance
      of
      the Series B Notes and (iii) the holder(s) of at least a majority of the
      aggregate outstanding principal balance of the Series C Notes.  The
      failure of either party to exercise in any respect any right provided for herein
      shall not be deemed a waiver of any right hereunder.

     

    15.    
        Severability.  If
      any provision of this Agreement shall be held to be invalid, illegal or
      unenforceable, the validity, legality and enforceability of the remaining
      provisions shall in no way be affected or impaired thereby.  Further,
      the provision that is held to be invalid, illegal or unenforceable shall remain
      in effect as far as possible in accordance with the intention of the
      parties.

     

    16.    
        Governing
      Law.  This Agreement shall be governed by and construed in
      accordance with the laws of the State of Delaware applicable to contracts made
      and to be performed in the State of Delaware.

     

    17.    
        Binding
      Effect and Assignment.  This Agreement shall be binding upon and
      inure to the benefit of the parties hereto and their respective heirs,
      executors, administrators, legal representatives, successors and permitted
      assigns.  The Licensee may assign this Agreement without restriction,
      without the consent of the Licensor, and without any other restriction; and
      such
      assignee shall have all of the rights, privileges and benefits of this Agreement
      without the need to take any further action.

     

    18.    
        Notices.  Any
      notice contemplated herein or required or permitted to be given hereunder shall
      be made in the manner set forth in either the Series A Purchase Agreement,
      Series B Purchase Agreement or Series C Purchase Agreement, as applicable,
      and
      delivered, in the case of Licensee, at the addresses set forth on the signature
      pages to the Purchase Agreements or Series C Note, or to such other address
      as
      any party hereto may have last specified by written notice to the other party
      or
      parties.

     

    [Remainder
      of Page Intentionally Left Blank.]

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    
 

    
      
         

      

      
        11

        
          

        

      

      
         

      

    

     

    IN
      WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed
      in
      duplicate by their duly authorized representatives as an instrument under seal
      as of the date first above written.

     

    
 

    LICENSOR

    

    MATRITECH,
      INC.

    

    

    By:
      ______________________________

    Name:
        Stephen D. Chubb

    Title:
          Chief Executive Officer

    

     

     

    
 

    

    

    LICENSEE

    

    SDS
      CAPITAL GROUP SPC, LTD.,

    as
      Collateral Agent

    

    

    By:
      ______________________________

    Name:

    Title:

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    
      
         

      

      
        12

        
          

        

      

      
         

      

    

    Schedule
      A

    

    MATRITECH
      PATENT RIGHTS

     

    A.           
      U.S. Patent Rights

    U.S.
      Patent No. 5,989,826

    U.S.
      Patent No. 6,162,608

    U.S.
      Patent No. 6,410,247

    U.S.
      Patent No. 6,740,494

    U.S.
      Patent No. 5,965,376

    U.S.
      Patent No. 5,783,403

    U.S.
      Patent No. 5,882,876

    U.S.
      Patent No. 5,698,439

    U.S.
      Patent No. 5,686,562

    U.S.
      Patent No. 5,780,596

     

     

    
 

    B.           
      Foreign Patent Rights

     

    Australian
      Patent No.
      658,257

    Canadian
      Patent No.
      2,122,473

    
      European
        Patent No. 642668 (validated in Austria, Belgium, France, Germany, Italy,
        Ireland, Luxembourg, the Netherlands, Spain, and the United
        Kingdom)

      
        Japanese
          Patent No. 3,190,042

      

      
        Australian
          Patent No. 681,855

      

      
        European
          Patent No. 0647270 (validated in Belgium, France, Germany, Italy, Spain,
          and the
          United Kingdom)

         

         

      

    

     

     

     

     

     

     

     

     

     

     

     

     

     

    
      
         

      

      
        13

        
          

        

      

      
         

      

    

    
      Schedule
        B

    

     

    MATRITECH
      TRADEMARK RIGHTS

    

    A.    U.S.
      Trademark Rights

           
      NMP22® - US Trademark Registration No. 1,956,141

           
      NMP22® - US Trademark Registration No. 1,963,117

           
      BLADDERCHEK® - US Trademark Registration No. 2,811,238

    

     

     

    
 

    B.    Foreign
      Trademark Rights

    NMP22®
-
      EU Trademark Registration No. 66,399

    UNMP®
-
      JP Trademark Registration No. 3,332,669

    BLADDERCHEKTM
      - EU Trademark Application No. 2,648,772

    NMP22
      BLADDERCHEKTM - EU Trademark Application No. 4,240,636

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    
 

    
      
         

      

      
        14

        
          

        

      

      
         

      

    

    Schedule
      C

    

    MIT
      PATENT RIGHTS

    

     

    
 

    Foreign
      Patent Rights

    

    Canadian
      Patent No.
      1,341,466

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    
 

    
      
         

      

      
        15

        
          

        

      

      
         

      

    

    Schedule
      D

    

    MIT
      PATENT LICENSE PROVISIONS

    

    Article
      V - Reports and Records

     

    5.1
      LICENSEE shall keep full, true and accurate books of account containing all
      particulars that may be necessary for the purpose of showing the amounts payable
      to M.I.T. hereunder. Said books of account shall be kept at LICENSEE's principal
      place of business or the principal place of business of the appropriate Division
      of LICENSEE to which this Agreement relates. Said books and the supporting
      data
      shall be open at all reasonable times for five (5) years following the end
      of
      the calendar year to which they pertain, to the inspection of M.I.T. or its
      agents for the purpose of verifying LICENSEE's royalty statement or compliance
      in other respects with this Agreement.

     

    Article
      VII - Termination

     

    7.6
      Upon termination of this Agreement for any reason during the exclusive period,
      any sublicensee not then in default shall have the right to seek a license
      from
      M.I.T.

     

    Article
      XV – Miscellaneous Provisions

    

    15.1
      This Agreement
      shall be construed, governed, interpreted and applied in accordance with the
      laws of the Commonwealth of Massachusetts, U.S.A., except that questions
      affecting the construction and effect of any patent shall be determined by
      the
      law of the country in which the patent was granted.

     

    15.2
The
      parties
      hereto acknowledge that this Agreement sets forth the entire Agreement and
      understanding of the parties hereto as to the subject matter hereof, and shall
      not be subject to any change or modification except by the execution of a
      written instrument subscribed to by the parties hereto.

     

    15.3
The
      provisions of
      this Agreement are severable, and in the event that any provision of this
      Agreement shall be determined to be invalid or unenforceable under any
      controlling body of law, such invalidity or unenforceability shall not in any
      way affect the validity or enforceability of the remaining provisions
      hereof.

     

    15.4
LICENSEE
      agrees
      to mark the Licensed Products sold in the United States with all applicable
      United States patent numbers. All Licensed Products shipped to or sold in other
      countries shall be marked in such a manner as to conform with the patent laws
      and practice of the country of manufacture or sale.

     

    15.5
      The failure of
      either party to assert a right hereunder or to insist upon compliance with
      any
      term or condition of this Agreement shall not constitute a waiver of that right
      or excuse a similar subsequent failure to perform any such term or condition
      by
      the other party.

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    
      
         

      

      
        16

        
          

        

      

      
         

      

    

    Schedule
      E

    

    NOTICE
      OF LICENSE GRANT

    

    WHEREAS,
      Matritech, Inc. (“Licensor”), a Delaware corporation having a principal
      place of business at 330 Nevada Street, Newton, MA 02460, is the owner of the
      patent rights listed in Schedule A attached hereto, is the licensee of
      the patent rights listed in Schedule B attached hereto (collectively,
“Patent Rights”) and is the owner of the trademark rights listed in
Schedule C attached hereto (“Trademark Rights”); and

    

    WHEREAS,
      Licensor has entered into a “Second Amended and Restated Contingent License
      Agreement” (the “Agreement”) with SDS Capital Group SPC, Ltd., as
      collateral agent for the holders of certain notes (collectively, the
“Licensee”) on or about August ____, 2007.

    

    NOW,
      THEREFORE, let it be known by those present that, in consideration of
      the mutual promises and covenants set forth in the Agreement, and for other
      good
      and valuable consideration, the receipt and sufficiency of which is hereby
      acknowledged, and subject to the terms and conditions of the Agreement, Licensor
      has granted to Licensee, certain license rights under the Patent Rights and
      Trademark Rights as set forth in the Agreement.

    

    IN
      WITNESS WHEREOF, the parties hereto have caused this document to be
      duly executed on the dates first set forth above.

    

    

    LICENSOR

    

    MATRITECH,
      INC.

    

    

    By:
      ______________________________

    Name:

    Title:

    

    

    

    LICENSEE

    

    SDS
      CAPITAL GROUP SPC, LTD.,

    as
      Collateral Agent

    

    

    By:
      ______________________________

    Name:

    Title:

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    
 

    
      
         

      

      
        17

        
          

        

      

      
         

      

    

    Schedule
      F

    
 

    COPY
      OF MIT LICENSE AGREEMENT

    

    

    

    
 

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    
      
         

      

      
        18www.EXFILE.com  888.775.4789   MATRITECH, INC.  FORM 8K == EXHIBIT 4.5

    EXHIBIT
      4.5

     

    CONSENT
      OF THE MAJORITY HOLDERS OF 15% SECURED CONVERTIBLE PROMISSORY NOTES DATED
      JANUARY 13, 2006 AND DATED JANUARY 22, 2007

    

    This
      Consent is executed and delivered on this 31st day of August 2007 by and among
      Matritech, Inc. (the “Borrower”) and the undersigned holders of
      (i) a majority of the outstanding principal amount of those certain 15% Secured
      Convertible Promissory Notes issued by the Borrower on January 13, 2006 (the
      “Series A Notes”) pursuant to the Securities Purchase
      Agreement, dated as of January 13, 2006, by and among the Borrower and the
      purchasers party thereto and previously amended on January 22, 2007 and July
      27,
      2007 (the “Series A Purchase Agreement”); and (ii) a majority
      of the outstanding principal amount of those certain 15% Secured Convertible
      Promissory Notes issued by the Borrower on January 22, 2007 (the “Series
      B Notes”) pursuant to the Securities Purchase Agreement, dated as of
      January 22, 2007, by and among the Borrower and the purchasers party thereto
      and
      previously amended on July 27, 2007 (the “Series B Purchase
      Agreement”).  The undersigned holders of a majority of the
      outstanding principal amount of the Series A Notes shall be referred to as
      the
“Series A Majority Holders.”  The
      undersigned holders of a majority of the outstanding principal amount of the
      Series B Notes shall be referred to as the “Series B
Majority Holders.”  All
      capitalized terms used in this Consent but not otherwise defined herein shall
      have the meanings ascribed to such terms in the Series A Purchase Agreement
      and
      the Series B Purchase Agreement, respectively.

    

    WHEREAS,
      the Borrower will enter into an Asset Purchase Agreement (the “Asset
      Purchase Agreement”), by and among Inverness Medical Innovations, Inc.
      (“Inverness”), Milano Acquisition Corp., and the Borrower,
      dated on or around the date hereof, under which the Borrower will agree to
      sell
      substantially all of its assets to Milano Acquisition Corp., in exchange for
      an
      initial payment of shares of Inverness common stock valued at approximately
      $36
      million (the “Inverness Shares”);

    

    WHEREAS,
      after the closing under the Asset Purchase Agreement (the “Asset
      Purchase Closing”), the Borrower intends to resell the Inverness Shares
      under a Form S-3 registration statement as soon as reasonably practicable in
      order to repay the amounts owed under the Series A Notes and the Series B Notes
      and to satisfy the Borrower’s other obligations; and

    

    WHEREAS,
      the parties have determined that it is in the best interests of the Borrower
      and
      all the holders of each of the Series A Notes and the Series B Notes that the
      following consents and directions be made;

    

    NOW,
      THEREFORE, for good and valuable consideration, the receipt and legal
      sufficiency of which is hereby acknowledged, the parties agree as
      follows:

     

    1.           Pursuant
      to the provisions of Section 8(c) of the Series A Purchase Agreement and the
      Series B Purchase Agreement, the Series A Majority Holders and the Series B
      Majority Holders hereby direct the Collateral Agent, immediately prior to the
      Asset Purchase Closing, to release the existing Collateral (as defined in the
      Security Documents), terminate the existing Security Documents, including the
      Contingent License Agreement and terminate the existing 

     

     

     

     

    
      
        
        

      

      
        1

        
          

        

      

      
        
        

      

    

    UCC-1
      financing statements filed pursuant to the existing Security Documents, copies
      of which are attached hereto as Exhibit A.

    

    2.           Pursuant
      to the provisions of Section 8(c) of the Series A Purchase Agreement and the
      Series B Purchase Agreement, the Series A Majority Holders and the Series B
      Majority Holders hereby direct the Collateral Agent, immediately prior to the
      Asset Purchase Closing, to enter into the Pledge Agreement attached hereto
      as
Exhibit B, pursuant to which the Borrower will grant to the Collateral
      Agent for the benefit of the holders of the Series A Notes and the Series B
      Notes (i) that number of Inverness Shares evidenced by the stock certificate
      referred to in the Pledge Agreement as would, upon the Asset Purchase Closing,
      have an aggregate value, valued as provided in the Asset Purchase Agreement,
      of
      150% of all the principal, interest and prepayment premiums owed in respect
      of
      the Series A Notes and the Series B Notes (the “Note Payment
      Amount”) and (ii) in the event the value of the pledged Inverness
      Shares is less than 120% of the Note Payment Amount for a period exceeding
      two
      consecutive trading days at any time prior to repayment in full of the Series
      A
      Notes and Series B Notes, grant to the Collateral Agent an additional number
      of
      Inverness Shares.  If the Borrower cannot provide the additional
      requisite number of shares equal to 150% of the Note Payment Amount, it will
      provide other acceptable substitute collateral, within three (3) business days
      after receipt of written demand from the Series A Majority Holders and the
      Series B Majority Holders.

    

    3.           Except
      as expressly set forth herein, (a) the original terms and conditions of the
      Series A Notes, as previously amended on January 22, 2007 and July 27, 2007,
      shall remain in full force and effect; (b) this Consent shall not be deemed
      to
      be a waiver, amendment or modification of, or consent to or departure from,
      any
      provision of the Series A Notes or to be a waiver of any Event of Default
      whether arising before or after the date hereof as a result of the transactions
      contemplated hereby; and (c) this Consent shall not preclude the future exercise
      of any right, remedy, power or privilege available to the holders of the Series
      A Notes whether under the Series A Notes or otherwise, and shall not be
      construed or deemed to be a satisfaction, novation, cure, modification,
      amendment or release of the Series A Notes.

    

    4.           Except
      as expressly set forth herein, (a) the original terms and conditions of the
      Series B Notes, as previously amended on July 27, 2007, shall remain in full
      force and effect; (b) this Consent shall not be deemed to be a waiver, amendment
      or modification of, or consent to or departure from, any provision of the Series
      B Notes or to be a waiver of any Event of Default whether arising before or
      after the date hereof as a result of the transactions contemplated hereby;
      and
      (c) this Consent shall not preclude the future exercise of any right, remedy,
      power or privilege available to the holders of the Series B Notes whether under
      the Series B Notes or otherwise, and shall not be construed or deemed to be
      a
      satisfaction, novation, cure, modification, amendment or release of the Series
      B
      Notes.

    

    5.           This
      Consent (a) constitutes the entire understanding of the parties with respect
      to
      the subject matter hereof, and any other prior agreements, whether written
      or
      oral, with respect hereto or thereto are expressly superseded hereby; (b) shall
      be governed by and construed in accordance with the laws of the State of
      Delaware without regard to principles of conflicts of laws; and (c) shall be
      binding upon and inure to the benefit of the successors and assigns of the
      Borrower and the holders of the Series A Notes and the holders of the Series
      B
      Notes.

     

     

     

    
 

    
      
        
        

      

      
        2

        
          

        

      

      
        
        

      

    

    6.           This
      Consent may be executed in multiple counterparts, each of which shall be deemed
      an original but all of which together shall constitute one and the same
      instrument, and by facsimile transmission, which facsimile signatures shall
      be
      considered original executed counterparts.

    

     

     

    
 

    [Remainder
      of Page Intentionally Left Blank]

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    
      
        
        

      

      
        3

        
          

        

      

      
        
        

      

    

    IN
      WITNESS WHEREOF, the undersigned Borrower and the Series A Majority Holders
      and
      the Series B Majority Holders have caused this Consent to be executed as of
      the
      day first above written.

     

    
 

    Borrower:

     

    
 

    Matritech,
      Inc.

     

    
 

    By:
/s/
      Stephen D.
      Chubb______________

    Name:   Stephen
      D.
      Chubb

    Title:     Chief
      Executive Officer

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    IN
      WITNESS WHEREOF, the undersigned Borrower and the Series A Majority Holders
      and
      Series B Majority Holders have caused this Consent to be executed as of the
      day
      first above written.

     

    
 

    Holders:

    

    SDS
      Capital Group SPC, Ltd., on behalf of its Class D
      segregated portfolio

    

    By:
      /s/ Steve
      Derby                                         

    Name: 
      Steve Derby

    Title:    Director

    Series
      A
      Notes Held: $1,323,333 
      principal

    Series
      B
      Notes Held: $1,140,000 principal

    

    

     

    ProMed
      Partners, L.P.

    

    By:
      /s/ David B.
      Musket                                 

    Name:  David
      B. Musket

    Title:    Managing
      Director

    Series
      A
      Notes Held: $131,476 
      principal

    Series
      B
      Notes Held: $320,399 
      principal

    

    

     

    ProMed
      Partners II, L.P.

    

    By:
      /s/ David B.
      Musket                                 

    Name:    David
      B. Musket

    Title:      Managing
      Director

    Series
      B
      Notes Held: $16,816 
      principal

    

    

     

    ProMed
      Offshore Fund, Ltd.

    

    By:
      /s/ David B.
      Musket                                 

    Name:  David
      B. Musket

    Title:    Managing
      Director

    Series
      A
      Notes Held: $22,539 principal

    Series
      B
      Notes Held: $48,072  principal

    

     

     

     

     

     

     

     

     

     

    
 

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    IN
      WITNESS WHEREOF, the undersigned Borrower and the Series A Majority Holders
      and
      Series B Majority Holders have caused this Consent to be executed as of the
      day
      first above written.

     

    
 

    ProMed
      Offshore Fund II, Ltd.

    

    By:
      /s/ David B.
      Musket                                 

    Name: 
      David B. Musket

    Title:     Managing
      Director

    Series
      A
      Notes Held: $835,569 
      principal

    Series
      B
      Notes Held: $414,713 
      principal

    

    
 

    David
      B. Musket, Individually

     

    /s/
      David B.
      Musket                                        

    Series
      A Notes Held:
      $106,875 principal

    Series
      B Notes Held:
      $250,000 principal

    

    

    

    H&Q
      Life Science Investors

    

    By:
      /s/ Daniel R.
      Omstead                              

    Name:    Daniel
      R. Omstead

    Title:      President

    Series
      A
      Notes Held: $1,583,333 
      principal

    Series
      B
      Notes Held: $1,000,000 
      principal

     

     

     

    
 

    The
      term
      H&Q Life Sciences Investors is the designation of the Trustees for the time
      being under a Declaration of Trust dated February 20, 1992, as amended, and
      all
      persons dealing with H&Q Life Sciences Investors must look solely to the
      trust property for the enforcement of any claims against H&Q Life Sciences
      Investors, and neither the Trustees, officers nor shareholders assume any
      personal liability for the obligations entered into on behalf of H&Q Life
      Sciences Investors.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}]]